WO2009017383A3 - Sustained-release formulation comprising metformin acid salt - Google Patents

Sustained-release formulation comprising metformin acid salt Download PDF

Info

Publication number
WO2009017383A3
WO2009017383A3 PCT/KR2008/004491 KR2008004491W WO2009017383A3 WO 2009017383 A3 WO2009017383 A3 WO 2009017383A3 KR 2008004491 W KR2008004491 W KR 2008004491W WO 2009017383 A3 WO2009017383 A3 WO 2009017383A3
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
sustained
acid salt
release formulation
oral administration
Prior art date
Application number
PCT/KR2008/004491
Other languages
French (fr)
Other versions
WO2009017383A2 (en
Inventor
Kwon Yeon Weon
Dong Wook Kim
Dong Seong Shin
Kyung Woon Kim
Original Assignee
Handok Pharmaceuticals Co Ltd
Kwon Yeon Weon
Dong Wook Kim
Dong Seong Shin
Kyung Woon Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Handok Pharmaceuticals Co Ltd, Kwon Yeon Weon, Dong Wook Kim, Dong Seong Shin, Kyung Woon Kim filed Critical Handok Pharmaceuticals Co Ltd
Publication of WO2009017383A2 publication Critical patent/WO2009017383A2/en
Publication of WO2009017383A3 publication Critical patent/WO2009017383A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to sustained-release formulation for oral administration, comprising metformin acid salt, more specifically sustained-release formulation for oral administration, and for treating or preventing diabetes mellitus and related diseases thereof, comprising metformin acid salt which lowers aqueous solubility of metformin as an active ingredient.
PCT/KR2008/004491 2007-08-02 2008-08-01 Sustained-release formulation comprising metformin acid salt WO2009017383A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070077696 2007-08-02
KR10-2007-0077696 2007-08-02

Publications (2)

Publication Number Publication Date
WO2009017383A2 WO2009017383A2 (en) 2009-02-05
WO2009017383A3 true WO2009017383A3 (en) 2009-04-09

Family

ID=40305070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/004491 WO2009017383A2 (en) 2007-08-02 2008-08-01 Sustained-release formulation comprising metformin acid salt

Country Status (3)

Country Link
KR (1) KR20090013736A (en)
TW (1) TW200906383A (en)
WO (1) WO2009017383A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110007984A (en) * 2009-07-17 2011-01-25 한올바이오파마주식회사 N,n-dimethyl imidodicarbonimidic diamide propionate, method of preparing the same, pharmaceutical composition comprising the same and combined formulation including the same
KR20110007985A (en) * 2009-07-17 2011-01-25 한올바이오파마주식회사 N,n-dimethyl imidodicarbonimidic diamide butyrate, method of preparing the same, pharmaceutical composition comprising the same and combined formulation including the same
FR3056908B1 (en) * 2016-09-30 2019-04-19 Nashpharm METFORMIN AND ELAFIBRANOR SALT HAVING DUAL ACTIVITY FOR THE TREATMENT OF OBESITY ASSOCIATED WITH NON-ALCOHOLIC STEATO-HEPATITIS (NASH) AND HYPERTRIGLYCERIDEMIA

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity

Also Published As

Publication number Publication date
KR20090013736A (en) 2009-02-05
TW200906383A (en) 2009-02-16
WO2009017383A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2011028947A3 (en) Heterocyclic compounds for the inhibition of pask
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
EP2340821A4 (en) Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2009080203A3 (en) Aminobenzamide derivatives as useful agents for controlling animal parasites
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
ATE523504T1 (en) 1-THIO-D-GLUCITOL DERIVATIVES
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
NO20082124L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2011012816A3 (en) Pharmaceutical formulation
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2011006935A3 (en) Tetrazole derivatives
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2012094462A3 (en) Heterocyclic compounds for the inhibition of pask
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08793005

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08793005

Country of ref document: EP

Kind code of ref document: A2